# EDGAR Filing Document

**Accession Number:** 0001855129
**File Stem:** 0001140361-25-037761
**Filing Date:** 2025-10
**Character Count:** 9495
**Document Hash:** 7748042b8f21ff9b4159e744f8de250f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-037761.hdr.sgml**: 20251009

**ACCESSION NUMBER**: 0001140361-25-037761

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251009

**FILED AS OF DATE**: 20251009

**DATE AS OF CHANGE**: 20251009

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GH Research PLC
- **CENTRAL INDEX KEY:** 0001855129
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40530
- **FILM NUMBER:** 251383609

**BUSINESS ADDRESS:**
- **STREET 1:** JOSHUA DAWSON HOUSE
- **STREET 2:** DAWSON STREET
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 RY95
- **BUSINESS PHONE:** 353 1 437 8334

**MAIL ADDRESS:**
- **STREET 1:** JOSHUA DAWSON HOUSE
- **STREET 2:** DAWSON STREET
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 RY95

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549
**FORM 6-K**<br>

#### REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

#### THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025.

#### Commission File Number: 001-40530

## GH Research PLC

#### (Exact name of registrant as specified in its charter)

#### Joshua Dawson House<br> Dawson Street

#### Dublin 2

#### D02 RY95

#### Ireland

#### (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ <br> Form 40-F ☐

------

GH Research PLC (the "Company") announces its participation at the 38<sup>th</sup> European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands.

A copy of the press release is attached hereto as Exhibit 99.1.

The fact that this press release is being made available should not be deemed an admission as to the materiality of any information contained therein. The information contained in the press release is being provided as of October 9, 2025, and the Company does not undertake any obligation to update the press release in the future or to update forward-looking statements to reflect subsequent actual results.

------

#### EXHIBIT INDEX

[99.1](ef20056751_ex99-1.htm) Press release dated October 9, 2025

------

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **GH Research PLC** | **GH Research PLC** |
| Date: October 9, 2025 |  |  |
|  | By: | /s/ Julie Ryan |
|  | Name: | Julie Ryan |
|  | Title: | Vice President, Finance |

---

------

## Exhibit 99.1

------

**Exhibit 99.1**<br>

#### GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
**Dublin, Ireland, October 9, 2025** – GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation at the 38<sup>th</sup> Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the Netherlands from October 11 – 14, where Professor Wiesław J. Cubała, MD, PhD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, will present long-term clinical data on the safety and efficacy from the open label extension (OLE) of a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (TRD) (GH001-TRD-201).

Additionally, two posters have been accepted presenting safety and tolerability data from the open-label extension part of GH001-TRD-201 as well as data on the psychoactive effects of GH001 in patients with TRD from GH001-TRD-201.

"*There remains a substantial unmet medical need for treatment-resistant depression, where many patients fail to achieve adequate relief with current therapies. In this context, the development of treatment options that combine strong efficacy, a favorable long-term safety profile, and a ra*pid-acting mechanism of action is particularly important*," said Professor Bernhard Baune, Director, Department of Psychiatry, University Hospital of Münster, Germany, and principal investigator in GH001-TRD-201. "*Re*sults from the 6-month open-label extension of GH001-TRD-201 provide important confirmation of GH001's safety and tolerability profile. Treatment was well tolerated, with no treatment-related serious adverse events reported and no evidence of treatment-emergent suicidal intent or behavior. These findings reinforce confidence in GH001 as a novel and rapid-acting approach for TRD."*

GH Research is also organizing an Industry Satellite Symposium to discuss the potential of rapid-acting antidepressants in TRD.

#### Details:

#### Novel Therapies Symposium Presentation (ECNP)
**Presentation Title:** Long-Term Data for GH001 in Patients with Treatment-Resistant Depression

**Presenting Author:** Wiesław J. Cubala, Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

**Date and Time:** October 13 from 3:00pm to 4:20pm CET

#### Poster (ECNP)
**Poster Title:** Psychoactive Effects of GH001 in Patients with Treatment-Resistant Depression: Results from a Phase 2b, Double-Blind, Randomized Controlled Trial

**Presenting Author:** Fabian Devlin, Mental Health Research for Innovation Centre, Mersey Care NHS Foundation Trust, United Kingdom

------

**Date and Time:** October 13 from 12:35pm to 2:00pm CET

**Poster Title:** Safety and Tolerability Results from a Phase 2b, Double-Blind Trial with an Open-Label Extension of GH001 in Treatment-Resistant Depression

**Presenting Author:** Bernhard T. Baune, Department of Psychiatry, University of Münster, Münster, Germany

**Date and Time:** October 14 from 12:35pm to 2:00pm CET

#### Industry Satellite Symposium

#### Title: Time Matters: The Potential of Rapid-Acting Antidepressants in Treatment-Resistant Depression
**Faculty Members:** (1) Prof Wiesław J. Cubała, MD, PhD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk; (2) Prof Michael E. Thase, MD, PhD, Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA, and Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia; (3) Prof Johannes G. Ramaekers, PhD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk; (4) Dr Lisa Harding, MD, Mood Institute, Milton, CT, USA, and Department of Psychiatry, Yale School of Medicine

**Date and Time:** October 12 from 8:40am to 10:00am CET

#### About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).

#### About GH001
Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our Phase 2b GH001-TRD-201 trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 (p<0.0001), we believe that GH001 has potential to change the way TRD is treated today.

------

#### Forward-Looking Statements
This press release contains statements that are, or may be deemed to be, forward-looking statements. All statements other than statements of historical fact included in this press release, including statements regarding our plans, strategies and prospects for our business, including the development and therapeutic potential of mebufotenin. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

#### Investor Relations
Julie Ryan

GH Research PLC

<u>investors@ghres.com</u>

------